Industry M&A Weekly: Pfizer's $10.5B China Bet, Autodesk Buys Ops Software, and Three More Deals

Week ending June 1, 2026 · Five disclosed deals across Biotech, SaaS, and Fintech

A crowded announcement window closed out May with three sector-defining deals on a single day (May 28), followed by reinforcing moves that clarify where acquirers are putting capital in 2026. Two cross-border biotech alliances worth a combined $21B, a record SaaS acquisition by an infrastructure software giant, a tax-compliance roll-up funded by Big Four, and a private equity platform bet on rights-management software.

Deal snapshot

Deal	Sector	Value	Structure
Pfizer × Innovent Biologics	Biotech	Up to $10.5B	Strategic collaboration + licensing
Eli Lilly × Curevo, Vaccine Company & LimmaTech	Biotech	Up to $3.85B (combined)	Three cash acquisitions with milestones
Autodesk × MaintainX	SaaS	$3.6B	All-cash acquisition
Fonoa × PwC Indirect Tax Edge + $110M Series C	Fintech	$110M raise (acquisition terms undisclosed)	Growth equity + product acquisition
Hg × Rightsline	SaaS	~$500M	PE strategic growth investment

Loading chart…

Pfizer and Innovent Biologics: the largest China-out oncology bet yet

On May 28, Pfizer struck a global strategic collaboration with Innovent Biologics, the Suzhou-based antibody specialist, valued at up to $10.5 billion — $650 million upfront plus $9.85 billion in milestones and royalties on approved products.1

The deal covers 12 early-stage oncology programs — eight Innovent-originated candidates plus four Pfizer-proposed discovery programs — spanning antibody-drug conjugates (ADCs) and multispecific antibodies. Innovent handles discovery and Phase 1 work; Pfizer takes global development and bears commercialisation costs after Phase 1.2 Rights outside greater China transfer to Pfizer on another four programs, with the remaining four split equally between both parties.

The strategic logic is clearly defensive as much as opportunistic. Since July 2025, six major pharma firms — GSK, Takeda, AstraZeneca, Eli Lilly, Bristol Myers Squibb, and now Pfizer — have collectively committed at least $8 billion each on broad multi-drug partnerships with Chinese biotechs. Innovent alone has now accumulated potential proceeds of over $30 billion across three separate alliances. For Pfizer, this is its largest China bet yet and a meaningful oncology pipeline injection after the Seagen acquisition's initial assets are progressing through trials. For Innovent, the deal validates that an asset-rich Chinese biotech can act simultaneously as supplier, co-developer, and future royalty collector.

The read-through for investors: Chinese ADC and multispecific antibody science has matured past the "interesting early-stage" label. Western pharma is now paying formation-stage multibillion-dollar tickets to secure access before those assets enter pivotal trials.

Blue-lit laboratory — test tubes and analysis equipment used in pharmaceutical research — Pharmaceutical research lab environment, illustrating the ADC and antibody discovery processes central to Western pharma's China licensing wave 1

Eli Lilly's three-vaccine shopping trip

On May 26, just two days before the Pfizer-Innovent announcement, Eli Lilly disclosed three simultaneous acquisitions totalling up to $3.85 billion to rebuild an infectious disease prevention franchise it exited years ago.3

Curevo (up to $1.5B): a next-generation shingles vaccine candidate, Amezosvatein, designed for better tolerability than existing Shingrix-class options.
Vaccine Company, Inc. (up to $1.55B): a five-antigen Epstein-Barr virus vaccine — the highest-value of the three, notable because EBV biology links to MS, multiple cancers, and long-term neurological risk.
LimmaTech Biologics (up to $780M): LTB-SA7, a Phase 1 vaccine targeting Staphylococcus aureus infections.4

None of the three are blockbuster near-term assets: all carry milestone-heavy, upfront-light structures, and the combined upfront cash was not disclosed. What the transaction pattern does signal is that Lilly — already the world's most valuable pharma company on the back of its GLP-1 franchise — is using its financial strength to plant multiple flags in adult immunisation, a market historically undervalued because prevention doesn't produce visible patient outcomes the way a disease treatment does. The EBV bet in particular carries long-horizon optionality: EBV vaccination sits at the intersection of infectious disease, oncology (EBV-associated lymphomas), and emerging neurology hypotheses around MS onset.

Autodesk acquires MaintainX for $3.6 billion

The same May 28 announcement window that produced the Pfizer deal also brought the largest SaaS acquisition of the year so far in the industrial vertical: Autodesk agreed to buy MaintainX for $3.6 billion in cash, funded through a combination of cash on hand and new debt.5 6

MaintainX is a San Francisco-based maintenance and operations platform — think of it as the CMMS (computerised maintenance management system) rebuilt for mobile and cloud. Its software manages work orders, asset histories, inspections, and operational workflows for industrial facilities ranging from food manufacturers to hospitals. The company expects to exceed $135 million in ARR for 2026, growing above 50%.

For Autodesk, the case is a lifecycle extension play. Autodesk's existing business sits at the design and construction end of the asset lifecycle — architects, engineers, and project managers use its tools to create buildings and infrastructure. MaintainX sits at the operations end, capturing what happens to those assets after handoff. The combined entity, which Autodesk plans to brand Autodesk Operations Solutions (AOS), would follow a building from blueprint through construction and into decades of maintenance. This matters strategically because operations contracts are recurring and sticky in ways that construction-phase licenses are not.

The deal also reads as Autodesk's bet on AI-driven convergence. MaintainX generates high-frequency operational data — maintenance histories, sensor-tied inspections, equipment failure patterns — that can feed predictive models. Autodesk already positions its digital twin ambitions around AI; MaintainX provides the real-world operational data layer those models require.

At roughly 26× forward ARR, the multiple signals strong market recovery in enterprise operations software, a segment that was hit hard during the post-2021 SaaS reset. Last year's deal droughts in vertical SaaS appear to be closing.

SaaS analytics dashboard on a laptop screen in a modern office setting — Enterprise software analytics dashboard — the kind of operational intelligence layer MaintainX provides and Autodesk is buying access to 6

Fonoa buys PwC's tax platform and raises $110 million

On May 28, Dublin-registered Fonoa completed the acquisition of PwC's Indirect Tax Edge product — an enterprise VAT and GST compliance tool used by large multinationals — while simultaneously announcing a $110 million Series C led by Headline, with new investors Eurazeo and Forestay Capital joining existing backers including Index Ventures, Coatue, and Dawn Capital.7 8

Neither the acquisition price for Indirect Tax Edge nor Fonoa's post-money valuation was disclosed.

The structural rationale is straightforward. Most enterprise tax teams run compliance on a patchwork: one tool per country, one system per regulatory step, spreadsheets for cross-border reconciliation. That patchwork held up when tax reporting was quarterly and national. It is breaking down as governments across the EU, Latin America, Southeast Asia, and India move to real-time e-invoicing and transaction-level reporting — a regulatory shift that has accelerated sharply since 2024.

Indirect Tax Edge provides best-in-class periodic compliance across the largest multinational client base; Fonoa provides real-time reporting infrastructure. Together, the pitch is a single data model that covers the full indirect tax lifecycle — from live transaction reporting to periodic VAT return — without making existing Edge customers start over.

That PwC chose to sell a live enterprise product rather than build the real-time layer itself is the detail that carries the most weight. It suggests that a Big Four firm with consulting depth concluded that infrastructure-layer real-time compliance is now a specialist software problem, not a professional services extension.

For fintech watchers, Fonoa sits inside a larger consolidation pattern in regulatory technology and tax infrastructure, as the B2B compliance stack becomes too complex and too cross-border to be served by professional services firms alone.

Hg acquires Rightsline for ~$500 million

Private equity software specialist Hg agreed to acquire Rightsline, a Los Angeles-based rights and royalties management SaaS provider, in a strategic growth investment valued at approximately $500 million including debt.9 10

Rightsline manages the complex rights, royalty, and IP licensing workflows for media companies, publishers, gaming studios, and distributors — tracking who owns what across territories, formats, and time windows. The business is highly complex and deeply sticky; clients who embed a rights-management system into their licensing operations rarely migrate.

Hg's investment thesis follows its established playbook: acquire mission-critical vertical SaaS with high switching costs, double the product's AI roadmap investment, and expand internationally using Hg's transatlantic network. Two Hg executives are joining Rightsline's board as part of the deal.

The transaction is a signal that Hg — a firm focused almost exclusively on B2B software — views AI-augmented rights intelligence as a durable growth market as media companies globalise licensing and face growing demand for granular royalty reporting from streaming, sub-licensing, and multi-territory deals. After a quieter period in PE software M&A during 2024-2025, the Rightsline deal, combined with Autodesk-MaintainX, suggests renewed appetite for vertical SaaS at meaningful multiples.

Three themes worth tracking

1. China biotech as the global ADC pipeline. The Pfizer-Innovent deal is the sixth deal of $8B+ between a Western pharma and a Chinese biotech since mid-2025. This is no longer an opportunistic footnote; it is a structural shift in where early-phase oncology pipeline is being assembled. The pattern carries regulatory risk (ongoing Washington scrutiny of Chinese biotech partnerships) and execution risk (Phase 1 failure rates), but the volume and dollar commitment suggest Western pharma has decided that risk is acceptable.

2. SaaS acquisition math is working again. The Autodesk-MaintainX deal at 26× ARR and the Hg-Rightsline deal at roughly $500M for a vertical software specialist both close at multiples that would have been unremarkable in 2021 and unthinkable in 2023. The combination of rising ARR growth at durable vertical SaaS businesses, lower debt costs than 2023-2024, and strategic acquirers with cash-rich balance sheets (Autodesk lifted full-year guidance the same day it announced the deal) is reopening the SaaS M&A window.

3. Compliance infrastructure is consolidating fast. Fonoa-PwC Indirect Tax Edge is one of several transactions in 2026 where a specialist fintech is absorbing an enterprise product from a Big Four firm. The direction of movement — from professional services to product company — suggests that compliance-intensive workflows (tax, AML, regulatory reporting) are migrating from consulting-delivered solutions to software platforms. For investors, the watch list is which other compliance verticals (transfer pricing, employment tax, customs) follow the same consolidation path.